Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

ACAD Relative to the S&P 500

ACAD Relative to the Sector

% of Revenue Generated in Each Quarter

% of Free Cash Flow Generated in Each Quarter

% of Net Income Generated in Each Quarter

Seasonal Chart Analysis

Analysis of the Acadia Pharmaceuticals Inc. (NASD:ACAD) seasonal charts above shows that a Buy Date of November 22 and a Sell Date of February 14 has resulted in a geometric average return of 17.67% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 16 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 23.03% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

ACADIA Pharmaceuticals, Inc. engages in the development and commercialization of medicines for central nervous system disorders. Its products include Nuplazid, which is used for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. The company was founded by Mark R. Brann on July 16, 1993 and is headquartered in San Diego, CA.

To download ACAD seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: ACAD